Table 1.

Pairwise comparison results from network meta-analysis on major adverse cardiovascular events.

Albiglutide

1.07 (0.9–1.28)

1.19 (1–1.42)

1.13 (0.94–1.35)

1.1 (0.9–1.35)

1.24 (1.03–1.51)

1.17 (0.99–1.38)

1.12 (0.93–1.33)

1.31 (1.07–1.59)

1.01 (0.71–1.46)

1.28 (1.11–1.48)

0.99 (0.79–1.23)

0.95 (0.72–1.26)

0.93 (0.78–1.11)

Canagliflozin

1.11 (0.96–1.28)

1.05 (0.9–1.22)

1.03 (0.86–1.23)

1.16 (0.98–1.37)

1.09 (0.94–1.25)

1.04 (0.89–1.21)

1.21 (1.03–1.44)

0.94 (0.66–1.34)

1.19 (1.08–1.32)

0.92 (0.75–1.12)

0.88 (0.68–1.15)

0.84 (0.71–1)

0.9 (0.78–1.04)

Dapagliflozin

0.95 (0.81–1.1)

0.92 (0.77–1.1)

1.04 (0.88–1.23)

0.98 (0.85–1.12)

0.94 (0.8–1.09)

1.1 (0.92–1.3)

0.85 (0.6–1.21)

1.08 (0.97–1.19)

0.83 (0.68–1.01)

0.8 (0.61–1.04)

0.89 (0.74–1.06)

0.95 (0.82–1.11)

1.06 (0.91–1.23)

Dulaglutide

0.98 (0.81–1.18)

1.1 (0.93–1.31)

1.03 (0.89–1.2)

0.99 (0.84–1.16)

1.16 (0.97–1.38)

0.9 (0.63–1.28)

1.14 (1.01–1.27)

0.88 (0.71–1.07)

0.84 (0.64–1.1)

0.91 (0.74–1.11)

0.97 (0.82–1.17)

1.08 (0.91–1.29)

1.02 (0.85–1.23)

Empagliflozin

1.13 (0.93–1.37)

1.06 (0.89–1.26)

1.01 (0.84–1.21)

1.19 (0.97–1.45)

0.92 (0.64–1.32)

1.16 (1.01–1.34)

0.9 (0.72–1.12)

0.86 (0.65–1.15)

0.8 (0.66–0.98)

0.86 (0.73–1.02)

0.96 (0.81–1.13)

0.91 (0.76–1.08)

0.89 (0.73–1.08)

Ertugliflozin

0.94 (0.8–1.1)

0.9 (0.75–1.07)

1.05 (0.87–1.27)

0.81 (0.57–1.17)

1.03 (0.9–1.18)

0.79 (0.64–0.98)

0.76 (0.58–1.01)

0.86 (0.72–1.01)

0.92 (0.8–1.06)

1.02 (0.89–1.17)

0.97 (0.83–1.12)

0.95 (0.79–1.12)

1.07 (0.91–1.25)

Exenatide

0.96 (0.83–1.1)

1.12 (0.95–1.32)

0.87 (0.61–1.23)

1.1 (1–1.21)

0.85 (0.7–1.03)

0.81 (0.63–1.06)

0.9 (0.75–1.07)

0.96 (0.83–1.12)

1.07 (0.92–1.24)

1.01 (0.86–1.18)

0.99 (0.82–1.19)

1.11 (0.94–1.32)

1.05 (0.91–1.21)

Liraglutide

1.17 (0.98–1.4)

0.91 (0.64–1.29)

1.15 (1.03–1.28)

0.89 (0.72–1.08)

0.85 (0.65–1.11)

0.77 (0.63–0.93)

0.82 (0.69–0.98)

0.91 (0.77–1.08)

0.86 (0.72–1.03)

0.84 (0.69–1.03)

0.95 (0.79–1.15)

0.89 (0.76–1.05)

0.85 (0.72–1.02)

Lixisenatide

0.78 (0.54–1.11)

0.98 (0.86–1.12)

0.76 (0.61–0.94)

0.73 (0.55–0.96)

0.99 (0.69–1.42)

1.06 (0.75–1.51)

1.18 (0.83–1.67)

1.11 (0.78–1.58)

1.09 (0.76–1.56)

1.23 (0.86–1.76)

1.15 (0.81–1.63)

1.1 (0.77–1.56)

1.29 (0.9–1.85)

Osemaglutide

1.27 (0.91–1.77)

0.97 (0.67–1.41)

0.94 (0.62–1.42)

0.78 (0.68–0.9)

0.84 (0.76–0.93)

0.93 (0.84–1.03)

0.88 (0.79–0.99)

0.86 (0.74–0.99)

0.97 (0.85–1.11)

0.91 (0.83–1)

0.87 (0.78–0.97)

1.02 (0.89–1.17)

0.79 (0.57–1.1)

Placebo

0.77 (0.65–0.91)

0.74 (0.58–0.95)

1.01 (0.81–1.26)

1.09 (0.9–1.33)

1.21 (0.99–1.47)

1.14 (0.93–1.4)

1.12 (0.89–1.39)

1.26 (1.02–1.56)

1.18 (0.97–1.43)

1.13 (0.92–1.38)

1.32 (1.07–1.64)

1.03 (0.71–1.49)

1.3 (1.1–1.54)

Sotagliflozin

0.96 (0.71–1.29)

1.05 (0.8–1.4)

1.13 (0.87–1.48)

1.26 (0.96–1.64)

1.19 (0.91–1.56)

1.16 (0.87–1.54)

1.31 (0.99–1.73)

1.23 (0.95–1.6)

1.17 (0.9–1.54)

1.38 (1.04–1.82)

1.07 (0.71–1.61)

1.35 (1.06–1.73)

1.04 (0.77–1.4)

Ssemaglutide